Equities Analysts Issue Forecasts for BioCryst Pharmaceuticals, Inc.’s Q2 2024 Earnings (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Stock analysts at HC Wainwright raised their Q2 2024 earnings per share estimates for BioCryst Pharmaceuticals in a report issued on Tuesday, May 7th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings of ($0.14) per share for the quarter, up from their prior estimate of ($0.16). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ Q3 2024 earnings at ($0.10) EPS, Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.51) EPS, FY2025 earnings at ($0.08) EPS and FY2026 earnings at $0.43 EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.06. The company had revenue of $92.80 million for the quarter, compared to the consensus estimate of $85.62 million. During the same quarter in the previous year, the company posted ($0.28) EPS. The business’s revenue was up 34.9% on a year-over-year basis.

Several other research analysts have also recently weighed in on BCRX. JMP Securities increased their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a report on Tuesday. Needham & Company LLC reissued a “buy” rating and set a $12.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

BioCryst Pharmaceuticals Stock Performance

BCRX opened at $5.10 on Thursday. The firm has a market capitalization of $1.05 billion, a PE ratio of -4.77 and a beta of 1.96. BioCryst Pharmaceuticals has a 52-week low of $4.03 and a 52-week high of $8.96. The business’s 50-day simple moving average is $4.89 and its 200 day simple moving average is $5.45.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in BioCryst Pharmaceuticals by 15.4% in the fourth quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock valued at $106,405,000 after purchasing an additional 2,371,401 shares during the last quarter. Avoro Capital Advisors LLC raised its position in BioCryst Pharmaceuticals by 13.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company’s stock valued at $78,170,000 after purchasing an additional 1,500,000 shares during the last quarter. Braidwell LP raised its position in BioCryst Pharmaceuticals by 6.6% in the fourth quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company’s stock valued at $34,254,000 after purchasing an additional 355,497 shares during the last quarter. Kynam Capital Management LP raised its position in BioCryst Pharmaceuticals by 46.8% in the fourth quarter. Kynam Capital Management LP now owns 4,600,000 shares of the biotechnology company’s stock valued at $27,554,000 after purchasing an additional 1,466,807 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C raised its position in BioCryst Pharmaceuticals by 148.6% in the third quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company’s stock valued at $23,265,000 after purchasing an additional 1,964,000 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.